Coya Therapeutics, Inc.
COYA
$4.93
-$0.31-5.92%
| Weiss Ratings | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.42 | |||
| Price History | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -24.62% | |||
| 30-Day Total Return | -30.37% | |||
| 60-Day Total Return | -11.65% | |||
| 90-Day Total Return | -24.39% | |||
| Year to Date Total Return | -13.66% | |||
| 1-Year Total Return | -46.06% | |||
| 2-Year Total Return | 20.16% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -51.86% | |||
| 52-Week Low % Change | 6.02% | |||
| Price | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.24 | |||
| 52-Week Low Price | $4.65 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Oct 28, 2024 | |||
| Valuation | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 82.45M | |||
| Enterprise Value | 44.11M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.99 | |||
| Earnings Per Share Growth | 19.93% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 22.70 | |||
| Price/Book (Q) | 2.08 | |||
| Enterprise Value/Revenue (TTM) | 12.41 | |||
| Price | $4.93 | |||
| Enterprise Value/EBITDA (TTM) | -2.57 | |||
| Enterprise Value/EBIT | -2.56 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 16.36M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 587 8170 | |||
| Address | 5850 San Felipe Street Houston, TX 77057 | |||
| Website | www.coyatherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2020 | |||
| Profitability | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -484.64% | |||
| Profit Margin | -418.69% | |||
| Management Effectiveness | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.15% | |||
| Return on Equity | -- | |||
| Income Statement | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.55M | |||
| Total Revenue (TTM) | 3.55M | |||
| Revenue Per Share | $0.22 | |||
| Gross Profit (TTM) | -8.31M | |||
| EBITDA (TTM) | -17.20M | |||
| EBIT (TTM) | -17.22M | |||
| Net Income (TTM) | -14.88M | |||
| Net Income Avl. to Common (TTM) | -14.88M | |||
| Total Revenue Growth (Q YOY) | -99.97% | |||
| Earnings Growth (Q YOY) | -330.32% | |||
| EPS Diluted (TTM) | -0.99 | |||
| EPS Diluted Growth (Q YOY) | -255.45% | |||
| Balance Sheet | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 38.34M | |||
| Cash Per Share (Q) | $2.34 | |||
| Total Current Assets (Q) | 44.31M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 39.58M | |||
| Current Ratio (Q) | 11.585 | |||
| Book Value Per Share (Q) | $2.37 | |||
| Total Assets (Q) | 44.35M | |||
| Total Current Liabilities (Q) | 3.82M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 4.77M | |||
| Total Common Equity (Q) | 39.58M | |||
| Cash Flow | COYA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -25.00K | |||
| Cash from Financing (TTM) | 16.03M | |||
| Net Change in Cash (TTM) | 5.71M | |||
| Levered Free Cash Flow (TTM) | -6.73M | |||
| Cash from Operations (TTM) | -10.29M | |||
